No excess risk of death or multimorbidity following hemorrhagic stroke after mRNA vaccination compared with historical cases: a population-based cohort study

While the association between hemorrhagic stroke and prior COVID-19 mRNA vaccination remains inconclusive, an examination of its prognosis may generate evidence on the potential causality of this relationship. If a causal link does exist, transient vaccine-related mechanisms (e.g., thrombocytopenia) might lead to a more favorable prognosis than naturally acquired cases. This study aimed to compare the prognosis of postvaccination hemorrhagic stroke and historical conventional cases with the same clinical diagnoses. A retrospective cohort study was conducted using a territory-wide electronic public healthcare database in Hong Kong, linked with population-based vaccination records. Since the roll-out of mRNA Vaccines (BNT162b2), patients aged 18 years or older hospitalized with hemorrhagic stroke within 28 days after mRNA vaccination were compared with conventional hemorrhagic stroke recorded between 2016 and 2017. The two-year follow-up period began from the diagnosis of hemorrhagic stroke. All-cause mortality and multimorbidity were examined using Cox proportional hazards models, with 95% confidence intervals (95%CIs) derived from bootstrap resampling (1,000 iterations). A total of 2,578 patients were included for analysis: 110 in the postvaccination group and 2,468 in the conventional group. Over the two-year follow-up period, all-cause death occurred in 27.27% (30/110) of the postvaccination group versus 29.78% (735/2,468) in the conventional group. Multimorbidity was observed in 63.64% (70/110) of postvaccination cases and 73.14% (1,805/2,468) of conventional cases, respectively. Adjusted analyses showed no significant differences in all-cause mortality (adjusted Hazard Ratio [aHR]=0.93, 95%CI:0.64-1.28) or multimorbidity risk (aHR=0.85, 95%CI:0.66-1.05) between the two groups. Hemorrhagic stroke following mRNA vaccination had a similar long-term prognosis with conventional cases. These findings may suggest that most post-vaccination hemorrhagic strokes are coincidental rather than vaccine-induced and do not confer a different prognosis.

Authors

Institutions

Publication Details

Journal
Brain Behavior & Immunity - Health
Published
2026-03-17
DOI
https://doi.org/10.1016/j.bbih.2026.101216
Primary Topic
Acute Ischemic Stroke Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

No excess risk of death or multimorbidity following hemorrhagic stroke after mRNA vaccination compared with historical cases: a population-based cohort study

Francisco Tsz Tsun Lai, Rachel Yui Ki Chu, Ian Chi Kei Wong, Xinya Mu et al.
Brain Behavior & Immunity - Health
Acute Ischemic Stroke Management
article

No excess risk of death or multimorbidity following hemorrhagic stroke after mRNA vaccination compared with historical cases: a population-based cohort study

Francisco Tsz Tsun Lai, Rachel Yui Ki Chu, Ian Chi Kei Wong, Xinya Mu, Yifang Huang, Wenlong Liu, Yuqi Hu, Boyan Liu, Lingyue Zhou, Wenxin Tian, Cuiling Wei, Song Song, Zijie Xu, Qi Sun
article en

Abstract

While the association between hemorrhagic stroke and prior COVID-19 mRNA vaccination remains inconclusive, an examination of its prognosis may generate evidence on the potential causality of this relationship. If a causal link does exist, transient vaccine-related mechanisms (e.g., thrombocytopenia) might lead to a more favorable prognosis than naturally acquired cases. This study aimed to compare the prognosis of postvaccination hemorrhagic stroke and historical conventional cases with the same clinical diagnoses. A retrospective cohort study was conducted using a territory-wide electronic public healthcare database in Hong Kong, linked with population-based vaccination records. Since the roll-out of mRNA Vaccines (BNT162b2), patients aged 18 years or older hospitalized with hemorrhagic stroke within 28 days after mRNA vaccination were compared with conventional hemorrhagic stroke recorded between 2016 and 2017. The two-year follow-up period began from the diagnosis of hemorrhagic stroke. All-cause mortality and multimorbidity were examined using Cox proportional hazards models, with 95% confidence intervals (95%CIs) derived from bootstrap resampling (1,000 iterations). A total of 2,578 patients were included for analysis: 110 in the postvaccination group and 2,468 in the conventional group. Over the two-year follow-up period, all-cause death occurred in 27.27% (30/110) of the postvaccination group versus 29.78% (735/2,468) in the conventional group. Multimorbidity was observed in 63.64% (70/110) of postvaccination cases and 73.14% (1,805/2,468) of conventional cases, respectively. Adjusted analyses showed no significant differences in all-cause mortality (adjusted Hazard Ratio [aHR]=0.93, 95%CI:0.64-1.28) or multimorbidity risk (aHR=0.85, 95%CI:0.66-1.05) between the two groups. Hemorrhagic stroke following mRNA vaccination had a similar long-term prognosis with conventional cases. These findings may suggest that most post-vaccination hemorrhagic strokes are coincidental rather than vaccine-induced and do not confer a different prognosis.

Brain Behavior & Immunity - HealthVol. 53
National University of Singapore (SG), Aston University (GB), Chinese University of Hong Kong (HK), University of Hong Kong (HK)
Good health and well-being
Openalex Percentile: Top 21%
Acute Ischemic Stroke Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.